0001209191-23-057239.txt : 20231204
0001209191-23-057239.hdr.sgml : 20231204
20231204165441
ACCESSION NUMBER: 0001209191-23-057239
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231130
FILED AS OF DATE: 20231204
DATE AS OF CHANGE: 20231204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rothera Mark
CENTRAL INDEX KEY: 0001550424
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51531
FILM NUMBER: 231464011
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS, INC.
STREET 2: 101 MAIN STREET, SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viracta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001061027
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943295878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
BUSINESS PHONE: 858-400-8470
MAIL ADDRESS:
STREET 1: 2533 S COAST HWY 101
STREET 2: SUITE 210
CITY: CARDIFF
STATE: CA
ZIP: 92007
FORMER COMPANY:
FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980709
FORMER COMPANY:
FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980501
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-30
0
0001061027
Viracta Therapeutics, Inc.
VIRX
0001550424
Rothera Mark
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF
CA
92007
1
1
0
0
President and CEO
0
Common Stock
2023-11-30
4
P
0
52094
0.494
A
52094
D
Common Stock
2023-12-01
4
P
0
47906
0.4932
A
100000
D
Represents the weighted average share price of an aggregate total of 52,094 shares purchased in the price range of $0.48 to $0.51 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average share price of an aggregate total of 47,906 shares purchased in the price range of $0.4750 to $0.5130 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Daniel Chevallard, as Attorney-in-Fact
2023-12-04